VIKING GLOBAL INVESTORS LP

October 14, 2026

Inhibrx to Present at Upcoming Scientific Conferences. Inhibrx Biosciences announced it will participate in upcoming scientific conferences. This event allows the company to share its research findings with the scientific community and industry peers. Such presentations are standard practice for biotech firms to maintain visibility and discuss their pipeline progress.

October 16, 2026

BridgeBio Reports Positive Phase 3 Data for Encaleret and Acoramidis. BridgeBio presented new data showing Encaleret improved symptoms in a Phase 3 trial for ADH1, with all participants reporting better outcomes than the standard of care. The company also shared real-world results for Acoramidis, indicating lower composite risk compared to tafamidis in ATTR-CM patients. These updates follow a recent 28% drop in the stock, which analysts suggest may be undervalued relative to their average target price.

October 17, 2026

APi Group Sets Q3 2026 Earnings Date, Citigroup Raises Target. APi Group has announced the date for its third‑quarter 2026 earnings release. Citigroup has lifted its price target to $55, citing the company’s strong fundamentals. Analysts view APi as a value option, with a 5‑year return that has outperformed many peers. The stock sits near its 52‑week high and is trading above the 200‑day moving average.

September 25, 2026

FDMT listed in Benzinga pre-market movers. 4D Molecular Therapeutics was mentioned in a Benzinga report on stocks moving lower in Friday’s pre-market session. The article grouped FDMT with other companies like Scholastic and Zscaler, noting a generally downbeat tone among legacy education and other large-cap names. This indicates the stock was part of a broader market movement rather than reacting to a company-specific announcement.

October 17, 2026

Roivant Sciences receives downgrades from Wolfe Research and analyst. Wolfe Research lowered Roivant Sciences to a peer‑perform rating. In the same week, an analyst who had been bullish on the company removed that stance, placing Roivant among a list of recent downgrades. The stock is now trading near its $28.03 support level with an RSI below 40, indicating limited upward momentum.

October 12, 2026

Amylyx to Present Phase 3 Avexitide Data at ObesityWeek 2026. Amylyx Pharmaceuticals is scheduled to present topline data from its Phase 3 LUCIDITY trial for avexitide at the ObesityWeek 2026 annual meeting. The data will focus on the drug's efficacy and safety in treating post-bariatric hypoglycemia. This upcoming presentation is a key catalyst for the company, as it provides new clinical evidence for a major therapeutic area.

September 25, 2026

THINK Surgical Names Rick McDowell VP of Sales. THINK Surgical, a subsidiary of PROCEPT BioRobotics, has appointed Rick McDowell as Vice President of Sales. This leadership addition is intended to support the company's commercial operations. The stock is currently trading near its 52-week low, with an average analyst target of $21.64.

October 16, 2026

Analysts Reassess AI Demand, Lift Ginkgo Bioworks Fair Value. Analysts have updated their view on Ginkgo Bioworks, raising its fair value after a renewed focus on AI applications in biotechnology. TD Cowen kept a hold rating but lifted its target price to $11, reflecting optimism about the company’s growth prospects. The stock has been trading below its 52‑week low and fell more than the broader market, suggesting investors are still cautious.

October 13, 2026

FIGS Q2 Earnings and Market Surge Push Stock to No.1 Apparel Rank. FIGS released its Q2 2026 earnings transcript, and the company has been highlighted as the top apparel stock in recent coverage. The shares jumped 6.5% and are now the highest‑valued apparel name in the market. Analysts note that the firm’s customer engagement strategy may help sustain its growth, while the broader market is shifting toward value stocks. The stock sits near its 52‑week high and is trading above a key support level.